On 21–23 September 2023, the Immuno-Cardiology Symposium was hosted by the Leducq Foundation Networks of Excellence Program (The Inflammatory-Fibrosis Axis in Adverse LV Remodeling: translating mechanisms into new diagnostics and therapeutics) at The Jackson Laboratory in Bar Harbor, Maine. The symposium highlighted recent advances in the basic science of dysregulated immune system activation and fibrosis in response to cardiac injury.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zaman, R. & Epelman, S. Immunity 55, 1549–1563 (2022).
Koenig, A. L. et al. Nat. Cardiovasc. Res. 1, 263–280 (2022).
Forte, E. et al. Circulation 143, 821–836 (2021).
Rieckmann, M. et al. J. Clin. Invest. 129, 4922–4936 (2019).
Kuppe, C. et al. Nature 608, 766–777 (2022).
Deng, Y. et al. Science 375, 681–686 (2022).
Kuwabara, J. T. et al. Elife 11, e69854 (2022).
Bowers, S. L. K. et al. Cells 12, 2174 (2023).
Tombor, L. S. et al. Nat. Commun. 12, 681 (2021).
Reboll, M. R. Science 376, 1343–1347 (2022).
Horckmans, M. et al. Circulation 137, 948–960 (2018).
Mohanta, S. K. et al. Nature 605, 152–159 (2022).
Hulsmans, M. et al. Science 381, 231–239 (2023).
Schiattarella, G. G. et al. Nature 568, 351–356 (2019).
Abel, E. D. Trans. Am. Clin. Climatol. Assoc. 129, 266–278 (2018).
Mas-Peiro, S. et al. Eur. Heart J. 44, 1943–1952 (2023).
Thackeray, J. T. et al. J. Am. Coll. Cardiol. 71, 263–275 (2018).
Koelwyn, G. J. et al. Nat. Med. 26, 1452–1458 (2020).
Mann, D. L. & Felker, G. M. Circ Res. 128, 1435–1450 (2021).
Forslund, S. K. et al. Nature 600, 500–505 (2021).
Ma, P. et al. Circulation 149, 48–66 (2024).
Rurik, J. G. et al. Science 375, 91–96 (2022).
Acknowledgements
The authors are part of the Immuno-Fib HF network. We are indebted to Immuno-Cardiology Symposium participants for their presentations and discussions and apologize to authors whose work we have not cited due to space restrictions. We thank M. Hoelscher for the photograph of the meeting attendees. We thank the contributions from the Jackson Laboratory, M. Hoelscher and L. Detering for the workshop arrangements. The symposium was supported by the Leducq Foundation, Washington University School of Medicine, University of Pennsylvania Perelman School of Medicine, Heidelberg University Hospital, RWTH Aachen University, Hannover Medical School, the International Society for Heart Research: North American Section, Amgen, Kiniksa, Vizgen, Novo Nordisk and SOFIE.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
J.A.E. holds equity in Capstan Therapeutics, a biotechnology company focused on developing mRNA approaches to generate CAR-T cells in vivo. R.K. is the founder and shareholder of Sequantrix GmbH and has grants from Travere Therapeutics, Galapagos, Chugai, AskBio and Novo Nordisk, and is a consultant for Bayer, Pfizer, Novo Nordisk, Hybridize Therapeutics and Gruenenthal. U.H. is one of the inventors of a pending patent application (PCT/EP2019/052952) filed by Universität Heidelberg for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine, and the description of the radiopharmaceuticals for use in the diagnosis or treatment of a disease characterized by overexpression of FAP in this manuscript is related to this patent application. U.H. holds shares of a consultancy group for iTheranostics. Y.L., R.G. and K.L. are inventors on a pending patent application (US17/001,857) filed by Washington University, and methods for detecting CCR2 receptor described in this manuscript are related to this patent application. Other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bengel, F., Epstein, J.A., Gropler, R. et al. Linking immune modulation to cardiac fibrosis. Nat Cardiovasc Res 3, 414–419 (2024). https://doi.org/10.1038/s44161-024-00459-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-024-00459-3